Loading [Contrib]/a11y/accessibility-menu.js
JHEOR
  • Menu
  • Articles
    • Author Correction
    • Autoimmune Diseases
    • Cardiovascular Conditions
    • Commentary
    • Correspondence
    • Dermatological Diseases
    • Endocrine Diseases
    • Gastrointestinal Conditions
    • General Indications
    • Hematology
    • Hereditary Genetic Disorders
    • Infectious Diseases
    • Methodology and Healthcare Policy
    • Nephrologic/Hepatologic Conditions
    • Neurological Diseases
    • Oncology
    • Ophthalmology
    • Other Conditions
    • Perspective
    • Psychological Conditions
    • Respiratory Diseases
    • Trauma Induced Conditions
    • Urological/Gynecological Diseases
    • All
  • For Authors
  • Editorial Board
  • About
  • Issues
  • Blog
  • Journal Policies
  • For Reviewers
  • search

    Sorry, something went wrong. Please try your search again.
    ×

    • Articles
    • Blog posts

RSS Feed

Enter the URL below into your favorite RSS reader.

https://jheor.org/feed
×
Urological/Gynecological Diseases
Vol. 5, Issue 2, 2018January 09, 2018 EDT

Clinical and Economic Evaluation of Transdermal Oxybutynin in the Treatment of Overactive Bladder in Spain

Carlos Crespo, Pedro Blasco, Marcelo Guigini, Jordi Galván,
oral muscarinic antagonists mirabegron persistence cost–effectiveness oxybutynin transdermal patch idiopathic overactive bladder
Copyright Logoccby-4.0 • https://doi.org/10.36469/9811
JHEOR
1.
Crespo C, Blasco P, Guigini M, Galván J. Clinical and Economic Evaluation of Transdermal Oxybutynin in the Treatment of Overactive Bladder in Spain. JHEOR. 2018;5(2):194-205. doi:10.36469/9811
Save article as...▾
  • PDF
  • XML
  • Citation (BibTeX)

View more stats

Powered by Scholastica, the modern academic journal management system